Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS). (Q37113720)

18 August 2017

1 reference

title

Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS). (English)

1 reference

18 August 2017

0 references

N Veys

1 reference

18 August 2017

W Van Biesen

series ordinal

1 reference

18 August 2017

N Lameire

series ordinal

1 reference

18 August 2017

language of work or name

1 reference

1 November 2007

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

396-407

1 reference

Pathogenesis of renal anemia

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Isolation and characterization of genomic and cDNA clones of human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Cloning and expression of the human erythropoietin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Recombinant EPO production--points the nephrologist should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Regulation of erythropoietin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Risks and benefits of erythropoiesis-stimulating agents in cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

The treatment of anemia in chronic kidney disease: understandings in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Role of anemia in progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Progression of nephropathy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Molecular control of iron transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Hepcidin in anemia and inflammation in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Iron management in nondialysis-dependent CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Clinical aspects of iron use in the anemia of kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Iron therapy for renal anemia: how much needed, how much harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Efficacy and safety of epoetin alfa in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Anemia and cardiovascular and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Emerging role of anemia in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

The interaction between heart failure and other heart diseases, renal failure, and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

The cardiovascular effects of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin regulates endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Mechanism of erythropoietin-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Influence of erythropoietin on dialyzer reuse, heparin need, and urea kinetics in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Epoetin-induced autoimmune pure red cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Bioequivalence and the immunogenicity of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Pure red-cell aplasia and epoetin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Anemia in diabetes: marker or mediator of microvascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Anemia with erythropoietin deficiency occurs early in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoiesis stimulating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Derivatives of erythropoietin that are tissue protective but not erythropoietic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

EPO: renoprotection beyond anemia correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin and treatment of non-anemic conditions--cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

New avenues of exploration for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin and the hypoxic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Carbamylated erythropoietin reduces radiosurgically-induced brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Correction of Anemia — Payoffs and Problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

Haemoglobin targets: we were wrong, time to move on

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FACB.2007.059

21 January 2018

Identifiers

DOI

10.1179/ACB.2007.059

1 reference

18 August 2017

1 reference